THE PIPELINE REPORT[removed]PHARMA’S FRONTRUNNERS Profiling a dozen agents on deck

First Page		Document Content
Date: 2013-05-21 21:35:48 Pyridines Benzamides Bristol-Myers Squibb Organofluorides Dipeptidyl peptidase-4 inhibitor Tofacitinib Pfizer GlaxoSmithKline Axitinib Chemistry Organic chemistry Carbamates		THE PIPELINE REPORT[removed]PHARMA’S FRONTRUNNERS Profiling a dozen agents on deck Add to Reading List Source URL: media.mmm-online.com Download Document from Source Website File Size: 133,15 KB Share Document on Facebook

	------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme DocID: 1m0Le - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STIVARGA safely and effectively. See full prescribing information for STIVARGA.  Dermatological toxicity: Interr DocID: 1lmpL - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use VOTRIENT safely and effectively. See full prescribing information for VOTRIENT. gastrointestinal perforation or DocID: 1lep2 - View Document
	Tofacitinib for chronic plaque psoriasis – second line DocID: 1dvG6 - View Document
	542 CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials DocID: 1anTs - View Document